Development of a CYP2C19 Genotype Guided Dosing Algorithm for Voriconazole

被引：0
|
作者：
Mangal, Naveen [1 ]
Hamadeh, Issam [2 ]
Samant, Tanay [1 ]
Schmidt, Stephan [1 ]
机构：
[1] Univ Florida, Coll Pharm, Ctr Pharmacometr & Syst Pharmacol, Orlando, FL USA
[2] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
T-031
引用
收藏
页码：S53 / S53
页数：1
相关论文
共 50 条
  • [41] Association of CYP2C19*17/*17 Genotype With the Risk of Voriconazole- Associated Squamous Cell Carcinoma
    Williams, Kiyanna
    Arron, Sarah T.
    JAMA DERMATOLOGY, 2016, 152 (06) : 719 - 720
  • [42] Combined Effect of CYP2C19 Genetic Polymorphisms and C-Reactive Protein on Voriconazole Exposure and Dosing in Immunocompromised Children
    Chen, Juan
    Wu, Ying
    He, Yuelin
    Feng, Xiaoqin
    Ren, Yuqiong
    Liu, Shiting
    FRONTIERS IN PEDIATRICS, 2022, 10
  • [43] EFFICACY OF FREQUENT PPI DOSING FOR HELICOBACTER PYLORI ERADICATION IN RELATION TO CYP2C19 GENOTYPE STATUS
    Sugimoto, M.
    Uotani, T.
    Yamade, M.
    Sahara, S.
    Ichikawa, H.
    Furuta, T.
    HELICOBACTER, 2012, 17 : 104 - 104
  • [44] Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy
    Empey, Philip E.
    Stevenson, James M.
    Tuteja, Sony
    Weitzel, Kristin W.
    Angiolillo, Dominick J.
    Beitelshees, Amber L.
    Coons, James C.
    Duarte, Julio D.
    Franchi, Francesco
    Jeng, Linda J. B.
    Johnson, Julie A.
    Kreutz, Rolf P.
    Limdi, Nita A.
    Maloney, Kristin A.
    Obeng, Aniwaa Owusu
    Peterson, Josh F.
    Petry, Natasha
    Pratt, Victoria M.
    Rollini, Fabiana
    Scott, Stuart A.
    Skaar, Todd C.
    Vesely, Mark R.
    Stouffer, George A.
    Wilke, Russell A.
    Cavallari, Larisa H.
    Lee, Craig R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (04) : 664 - 674
  • [45] APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF CYP2C19 SUBSTRATE VORICONAZOLE TO PREDICT EXPOSURES IN JAPANESE BY CYP2C19 PHENOTYPE.
    Muto, C.
    Yamazaki, S.
    Yu, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S44 - S45
  • [46] Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling
    Zubiaur, Pablo
    Kneller, Lisa A.
    Ochoa, Dolores
    Mejia, Gina
    Saiz-Rodriguez, Miriam
    Borobia, Alberto M.
    Koller, Dora
    Garcia, Irene Garcia
    Navares-Gomez, Marcos
    Hempel, Georg
    Abad-Santos, Francisco
    CLINICAL PHARMACOKINETICS, 2021, 60 (02) : 261 - 270
  • [47] Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling
    Pablo Zubiaur
    Lisa A. Kneller
    Dolores Ochoa
    Gina Mejía
    Miriam Saiz-Rodríguez
    Alberto M. Borobia
    Dora Koller
    Irene García García
    Marcos Navares-Gómez
    Georg Hempel
    Francisco Abad-Santos
    Clinical Pharmacokinetics, 2021, 60 : 261 - 270
  • [48] The impact of CYP2C19 genotype on phenoconversion by concomitant medication
    De Jong, Laura
    Boussallami, Soukayna
    Hawinkels, Luuk
    Hoekstra, Menno
    Tushuizen, Maarten
    Rissmann, Robert
    Swen, Jesse
    Manson, Martijn
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 1326 - 1327
  • [49] Does CYP2C19 genotype affect clinical outcome?
    Jurriën M. ten Berg
    Vera H. Deneer
    Nature Reviews Cardiology, 2012, 9 : 192 - 194
  • [50] CYP2C19 GENOTYPE SIGNIFICANTLY AFFECTS THE PHARMACOKINETICS OF TOLPERISONE
    Byeon, J.
    Lee, H.
    Choi, C.
    Lee, Y.
    Jang, C.
    Bae, J.
    Lee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S23 - S24
12345